Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.

The oncologist·2026

Same author

A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Systematic review of checkpoint inhibitor-induced epidermal necrolysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Same author

Safe prescribing in cancer patients during the COVID-19 pandemic and outcomes following restart of cancer care following SARS-CoV-2 infection: The COV-SPOT initiative.

International journal of cancer·2025

Same author

Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report.

Contemporary clinical trials communications·2024

Same author

Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024

Same journal

Boundary Erosion in Oncology Nursing: Psychosocial Consequences and Coping Strategies-A Qualitative Study.

Seminars in oncology nursing·2026

Same journal

Health-Related Quality of Life in Cancer Cachexia: Validation of the Turkish Version of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT).

Seminars in oncology nursing·2026

Same journal

A Dyadic Study of Lived Experiences of Family Stress, Emotional Distress and Family Resilience Among Women With Cancer During Pregnancy and Their Partners.

Seminars in oncology nursing·2026

Same journal

Rapid Reduction in Cancer Worry Through a Mindfulness-based Coping Programme: Evidence from a Randomised Trial with Women Awaiting Biopsy Results.

Seminars in oncology nursing·2026

Same journal

Refining Genomic Integration in Hereditary Breast Cancer: Reflections on Clinical and Nursing Implications.

Seminars in oncology nursing·2026

Same journal

Bridge Symptoms Between Symptom Clusters in Children with Acute Lymphoblastic Leukemia During Maintenance Therapy: A Network Analysis.

Seminars in oncology nursing·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 10, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Advanced Triple-Negative Breast Cancer.

Grisma Patel¹, Alison Prince², Mark Harries³

¹Medical Oncology Specialist Registrar, Doctor - Department of Oncology, Guys Cancer Centre, Guys and St Thomas' NHS Foundation Trust, London, UK.

Seminars in Oncology Nursing

|November 26, 2023

Summary

This summary is machine-generated.

Advances in treating advanced triple-negative breast cancer (TNBC) include new immunotherapies and targeted agents. Multidisciplinary care and nursing support are crucial for patients facing this aggressive disease.

Keywords:

Antibody–drug conjugate Immunotherapy Specialist nurse Targeted therapy Triple-negative breast cancer

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Experiment Videos

Last Updated: Jul 10, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Area of Science:

Oncology
Translational Research

Background:

Triple-negative breast cancer (TNBC) is an aggressive subtype with a poorer prognosis.
Understanding TNBC heterogeneity and signaling pathways is critical for treatment development.

Approach:

Review of peer-reviewed literature, clinical guidelines, and trial data.
Focus on novel therapeutic strategies and multidisciplinary patient management.

Key Points:

Chemotherapy is no longer the sole treatment for TNBC.
Emerging therapies include immunotherapy, targeted agents, and antibody-drug conjugates.
Multidisciplinary care is essential for optimal patient outcomes.

Conclusions:

New systemic therapies are expanding treatment options for advanced TNBC.
Nurses play a vital role in educating patients about new treatments and managing toxicities.
Addressing physical and psychosocial needs through comprehensive support services is paramount.